![POINT Biopharma Global Inc. logo](/logos/PNT.webp)
POINT Biopharma Global Inc.
NASDAQ:PNT
Overview | Financials
Company Name | POINT Biopharma Global Inc. |
Symbol | PNT |
Currency | USD |
Price | 12.5 |
Market Cap | 1,332,112,500 |
Dividend Yield | 0% |
52-week-range | 6.57 - 14.35 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Joe A. McCann Ph.D. |
Website | https://www.pointbiopharma.com |
An error occurred while fetching data.
About POINT Biopharma Global Inc.
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand,
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD